TY - JOUR T1 - Two B or not two B, that is the question. Statements in favor of the quadrivalent influenza vaccine JO - Vacunas T2 - AU - Van Ranst,M. SN - 15769887 M3 - 10.1016/j.vacun.2020.07.003 DO - 10.1016/j.vacun.2020.07.003 UR - https://www.elsevier.es/es-revista-vacunas-72-articulo-two-b-or-not-two-S1576988720300388 AB - Each year, over 1 billion people worldwide are affected by the influenza virus. Vaccination is the most effective method of protection against this disease. Although the WHO has included a quadrivalent influenza vaccine formulation in its official recommendations since 2013–2014, it is not yet widely used. The impact of influenza B viruses is underestimated. Nevertheless, they are responsible for 20–25% of influenza infections worldwide, causing similar clinical symptoms to influenza A that particularly affect the pediatric population. There is no way to predict which B virus lineage will be more prevalent each season. Consequently, the trivalent vaccine composition often fails to include the most prevalent B lineage in that season, and the vaccinated population is therefore not well protected against type B influenza. The quadrivalent influenza vaccine protects against four strains of influenza virus and will represent an opportunity to reduce the influenza burden. ER -